Log in
A commercial continuous glucose sensor/monitor that provides real time data has been developed by GlySure, a venture capital funded company founded on the basis of Bath chemistry. The sensor enables Tight Glycaemic Control (TGC) for control of glucose levels in patients in Intensive Care Units (ICUs), reducing severe hypoglycaemia, glycaemic variability and the nursing burden, maximising both patient and economic benefit. This has led to (i) £13.5M investment in the company GlySure Ltd directly for development of the system based on the Bath chemistry and (ii) successful results from full clinical trials of the device, involving more than 200 ICU patients, prior to CE approval and launch in the EU.